Sign in to fuzzto save your conversations, follow your research and come back anytime.

‌

‌
‌

‌
‌
‌

‌
‌

‌

‌
‌
‌
‌
‌
‌
‌

‌
‌
‌
‌
‌
‌

Sai Life Sciences Stock Price - ₹1,574.80 | Healthcare | askfuzz

S

Sai Life Sciences

SAILIFE•

NSE

BSE

SectorHealthcare

‌
‌
‌

₹1,574.80

+₹739.15(87.18%)•Past Year

Loading chart…

‌
‌
‌

‌
‌
‌

In the news

Sai Life Science hits new high, surges 8% in two days amid market volatility

Sai Life Science hits new high, surges 8% in two days amid market volatility

Trade Spotlight: 13 stocks for August 24 with technical targets

Trade Spotlight: 13 stocks for August 24 with technical targets

Sai Life Sciences Q1 profit jumps 21.22% to ₹73.29 crore

Sai Life Sciences Q1 profit jumps 21.22% to ₹73.29 crore

India's CDMO sector gains momentum with ChemT's $5M AI funding

India's CDMO sector gains momentum with ChemT's $5M AI funding

Healthcare stocks surge 27% in FY27, analysts see 17% upside potential

Healthcare stocks surge 27% in FY27, analysts see 17% upside potential

Sai Life, Laurus Labs hit new highs; rally up to 40% in 6 months

Sai Life, Laurus Labs hit new highs; rally up to 40% in 6 months

DLF gets 24% upside target despite soft annual bookings

DLF gets 24% upside target despite soft annual bookings

Sai Life Science shares crash 14% post Q4 results despite 109% profit jump

Sai Life Science shares crash 14% post Q4 results despite 109% profit jump

5 stocks crash up to 14% post Q4 results despite strong fundamentals

5 stocks crash up to 14% post Q4 results despite strong fundamentals

Expert stock picks: GMDC, HZL, IGIL recommendations updated

Expert stock picks: GMDC, HZL, IGIL recommendations updated

MarketSmith India Recommends 2 Stocks for April 24

MarketSmith India Recommends 2 Stocks for April 24

Sai Life Sciences Q3FY26 Earnings Call Set for Feb 6

Sai Life Sciences Q3FY26 Earnings Call Set for Feb 6

Insights

Company insights, generated from the most recent coverage.

Dedicated peptide development lab coming online soon; Greenfield peptide manufacturing facility planned for FY28 — positioning company in high-growth GLP-1 and peptide therapeutics segment.
Stock hits new all-time high of ₹1,579 with +3.8% gain today and +8% over two days on volume doubling to 1.4–2.3M shares — strong institutional buying momentum.
First Indian CRDMO to operate on 100% renewable energy (Bidar campus) — unique ESG moat attracting sustainability-focused global investors and potentially lowering long-term energy costs.

The Quarter story

The two most recent quarterly results, compared side-by-side.

Sai Life Sciences shows steady cost control and stronger CRO demand, though profits and margins are cooling after a strong peak.

CRO revenue share grows from 37% to 40% from Q1 FY26 to Q1 FY27 — stronger demand for research services

Consolidated revenue eases from ₹496 to ₹554 from Q1 FY26 to Q1 FY27 — seasonal order pacing after a Q4 peak

Finance costs fall from ₹12 to ₹8 from Q1 FY26 to Q1 FY27 — improved debt management

EBITDA margin contracts from 25% to 27% from Q1 FY26 to Q1 FY27 — cost normalization after a 34% peak in Q3

Forex impact improves from a ₹4 loss to a ₹1 gain from Q1 FY26 to Q1 FY27 — stabilized currency exposure

Profit after tax falls from ₹60 to ₹73 from Q1 FY26 to Q1 FY27 — seasonal earnings dip from a Q3 high

Capital work in progress rises from ₹134 to ₹263 from Q1 FY26 to Q1 FY27 — ongoing facility upgrades

EBITDA drops from ₹125 to ₹148 from Q1 FY26 to Q1 FY27 — temporary margin pressure after Q3 peak